1. A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. Issue 4 (9th September 2019) Authors: Eyre, Toby A.; Hildyard, Catherine; Hamblin, Angela; Ali, Ayesha S.; Houlton, Aimee; Hopkins, Louise; Royston, Daniel; Linton, Kim M.; Pettitt, Andrew; Rule, Simon; Cwynarski, Kate; Barrington, Sally F.; Warbey, Victoria; Wrench, David; Barrans, Sharon; Hirst, Caroline S.; Panchal, Anesh; Roudier... Journal: Hematological oncology Issue: Volume 37:Issue 4(2019) Page Start: 352 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Application of the LymphGen classification tool to 928 clinically and genetically‐characterised cases of diffuse large B cell lymphoma (DLBCL). (3rd October 2020) Authors: Runge, Hendrik F. P.; Lacy, Stuart; Barrans, Sharon; Beer, Philip A; Painter, Daniel; Smith, Alexandra; Roman, Eve; Burton, Cathy; Crouch, Simon; Tooze, Reuben; Hodson, Daniel J. Journal: British journal of haematology Issue: Volume 192:Number 1(2021) Page Start: 216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cell‐of‐origin in diffuse large B‐cell lymphoma: findings from the UK's population‐based Haematological Malignancy Research Network. (8th November 2018) Authors: Painter, Daniel; Barrans, Sharon; Lacy, Stuart; Smith, Alexandra; Crouch, Simon; Westhead, David; Sha, Chulin; Patmore, Russell; Tooze, Reuben; Burton, Cathy; Roman, Eve Journal: British journal of haematology Issue: Volume 185:Number 4(2019) Page Start: 781 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Cryptic 5q deletion in a patient with myelodysplastic syndrome. (14th March 2017) Authors: Medlock, Ruth; Barrans, Sharon; Cargo, Catherine; Kelly, Richard Journal: British journal of haematology Issue: Volume 177:Number 3(2017) Page Start: 347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial. Issue 1 (29th April 2020) Authors: Phillips, Elizabeth H.; Burton, Catherine; Kirkwood, Amy A.; Barrans, Sharon; Lawrie, Anthony; Rule, Simon; Patmore, Russell; Pettengell, Ruth; Ardeshna, Kirit M.; Montoto, Silvia; Paneesha, Shankara; Clifton‐Hadley, Laura; Linch, David C.; McMillan, Andrew K. Journal: EJHaem Issue: Volume 1:Issue 1(2020) Page Start: 133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial. Issue 1 (29th April 2020) Authors: Phillips, Elizabeth H.; Burton, Catherine; Kirkwood, Amy A.; Barrans, Sharon; Lawrie, Anthony; Rule, Simon; Patmore, Russell; Pettengell, Ruth; Ardeshna, Kirit M.; Montoto, Silvia; Paneesha, Shankara; Clifton‐Hadley, Laura; Linch, David C.; McMillan, Andrew K. Journal: EJHaem Issue: Volume 1:Issue 1(2020) Page Start: 133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial. Issue 1 (29th April 2020) Authors: Phillips, Elizabeth H.; Burton, Catherine; Kirkwood, Amy A.; Barrans, Sharon; Lawrie, Anthony; Rule, Simon; Patmore, Russell; Pettengell, Ruth; Ardeshna, Kirit M.; Montoto, Silvia; Paneesha, Shankara; Clifton‐Hadley, Laura; Linch, David C.; McMillan, Andrew K. Journal: EJHaem Issue: Volume 1:Issue 1(2020) Page Start: 133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Issue 5 (May 2019) Authors: Davies, Andrew; Cummin, Thomas E; Barrans, Sharon; Maishman, Tom; Mamot, Christoph; Novak, Urban; Caddy, Josh; Stanton, Louise; Kazmi-Stokes, Shamim; McMillan, Andrew; Fields, Paul; Pocock, Christopher; Collins, Graham P; Stephens, Richard; Cucco, Francesco; Clipson, Alexandra; Sha, Chulin; Tooze... Journal: Lancet oncology Issue: Volume 20:Issue 5(2019) Page Start: 649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The prognosis of MYC translocation positive diffuse large B‐cell lymphoma depends on the second hit. (30th March 2015) Authors: Clipson, Alexandra; Barrans, Sharon; Zeng, Naiyan; Crouch, Simon; Grigoropoulos, Nicholas F; Liu, Hongxiang; Kocialkowski, Sylvia; Wang, Ming; Huang, Yuanxue; Worrillow, Lisa; Goodlad, John; Buxton, Jenny; Neat, Michael; Fields, Paul; Wilkins, Bridget; Grant, John W; Wright, Penny; EI‐Daly, Hesha... Journal: Journal of pathology Issue: Volume 1:Number 3(2015) Page Start: 125 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗